Dexcom gets clearance for long-wearing CGM
By HME News Staff
Updated 2:10 PM CDT, Mon April 14, 2025
SAN DIEGO – Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall mean absolute relative difference (MARD) of 8%, Dexcom G7 15 Day builds on the performance of Dexcom CGM, which the company says is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range. “The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” said Jake Leach, executive vice president and COO at Dexcom. “By listening to the needs of our users, we’re proud to offer the longest lasting wearable and most accurate CGM, giving people the knowledge to better control their diabetes with our best-in-class technology. This milestone sets a new standard in CGM and is a testament to our continued leadership in glucose biosensing. We look forward to bringing it to market, but in the meantime, we encourage our users to upgrade to our current G7 system.” Dexcom is working closely with its insulin pump partners to ensure that Dexcom G7 15 Day will be compatible with automated insulin delivery systems upon launch. Dexcom G7 15 Day is expected to launch in the US in the second half of 2025.
Comments